Edison Investment Research - Ultimovacs (ULTI) Ultimovacs - Cancer vaccine with near-universal potential

Report

Edison Investment Research

Sean Conroy

Ultimovacs - Cancer vaccine with near-universal potential

Ultimovacs is a biotechnology company focused on developing a near-universal cancer vaccine. The lead asset UV1 activates the immune system to recognise cancer cells that express human telomerase reverse transcriptase (hTERT, or telomerase), which is expressed in over 85% of cancer types. In these malignancies, cell reproduction relies exclusively on hTERT maintaining the length of telomers. For this reason, UV1 has a broad potential in a variety of cancers, in different stages, and in combination with other treatments. Two Phase II trials in metastatic melanoma (UV1 plus ipilimumab and nivolumab) and mesothelioma (same combination) are ongoing, with results expected 2022. The third Phase II trial should be announced soon.

20/11/2020 2 EN

Underlying

Ultimovacs

Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.

See profile

NO0010851603 Oslo Bors Norway

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

GlobeNewsWire

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multi...

23h / 46m 23h / 46m 1 EN

GlobeNewsWire

Ultimovacs ASA – Annual General Meeting held on April 18, 2024

Ultimovacs ASA – Annual General Meeting held on April 18, 2024 Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons: Jónas Einarsson, Chair of the BoardHenrik Schüssler, board member Kari Grønås, board member Ketil Fjerdingen, deputy board member The Nomination Committee will consist of the following persons until the Annual General Meeting in 2025: Ole Kristian Hjelstue...

April 18, 2024 April 18, 2024 1 EN

Edison Investment Research

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direction. To remain funded to these milestones, the company has enforced stringent cost control measures...

April 18, 2024 April 18, 2024 1 EN

Henderson Far East Income - Repositioning to raise total returns

Henderson Far East Income (HFEL) has consistently delivered on its objective to provide a rising dividend. However, like many investors, HFEL’s managers overestimated the potential for a post-pandemic rebound in China. The trust’s resultant overweight to Chinese consumer and other cyclicals led to a fall in portfolio revenues and underperformance in the financial year ended 31 August 2023 (FY23). With a view to improving future returns, HFEL’s board has since indicated an increased willingness to use reserves when necessary to support dividend payments, which it did in FY23. This reduces the r...

3h / 16m 3h / 16m 1 EN

Richard Williamson

Richard Williamson

Freelancer - AI to drive return to growth

Freelancer’s Q124 results were mixed. Operationally, the company is seeing rising demand for AI specialists as customers seek affordable ways to develop proprietary AI. Notably, in Enterprise, the company delivered a large-scale AI pilot for a tech giant, sourcing 20,000 freelancers in 24 hours across 52 languages. This impressive achievement could lead to a substantial multi-year contract. Major initiatives across Loadshift and Escrow with leading organisations are set to be deployed over the coming months, potentially catalysing performance and diversifying revenue streams. We revise our for...

4h / 19m 4h / 19m 1 EN

Toby Thorrington

Toby Thorrington

Renewi - Solid trading and better cash generation

Renewi’s FY24 trading update was in line with management’s expectations and its improved cash generation is reassuring for investors. Attention is now likely to turn the strategic review of the UK Municipals with management stating that they remain on track to update markets by the end of June. This could lead to an exit of key liabilities and leave Renewi as an attractive circular economy investment with strong market positions and organic growth plans, which should assist in generating value, including a potential re-rating of the shares.

4h / 22m 4h / 22m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Ultimovacs - Cancer vaccine with near-universal potential

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Ultimovacs ASA – Annual General Meeting held on April 18, 2024

Ultimovacs - Steadfast commitment to UV1 progression

Henderson Far East Income - Repositioning to raise total returns

Freelancer - AI to drive return to growth

Renewi - Solid trading and better cash generation

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe